March 23, join Cyxone at Swiss Nordic Bio – a high-level partnering and investor conference aimed at connecting healthcare innovations, investor and industry.
Read More

See CEO Tara Heitner’s presentation at Redeye InvestorForum on 13 January 2022

Read More

Cyxone will attend the Swiss Nordic Bio on 23 March 2022 – Connecting Healthcare Innovations, Investors and Industry

Read More

Cyxone – Building stronger, safer bridges to health

Treatments for diseases such as rheumatoid arthritis, multiple sclerosis and virally induced acute respiratory disorders such as Covid 19 have come a long way but still have several shortcomings. These include adverse side effects, administration forms that often require visits to the hospital, and poor response or resistance in some patients. Cyxone is a clinical-stage biotech company focusing on the development of treatments that are administered early stage, have fewer, less severe side effects, can be taken on an outpatient basis and are showing promising response in early clinical trials. To put it simply, Cyxone’s treatments will increase the quality of life for millions of people.

Our Drug Projects

Rheumatoid Arthritis (Rabeximod)

A unique mechanism-of-action combined with a convenient oral administration and a beneficial tolerability profile

Read More

Covid-19 (Rabeximod)

Inhibits the release of multiple cytokines without suppressing the general immune system

Read More

Multiple sclerosis (T20K)

Acts to stop or slow down the progression of multiple sclerosis

Read More

CEO Tara Heitner comments

“All in all, we are facing an eventful time period in the near future, with each step taking us closer to reaching our goal of providing millions of patients suffering from debilitating diseases with better therapies.”

Read More